A pill after transplant: new hope to stop t-cell cancer relapse
NCT ID NCT07774377
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This trial tests whether taking chidamide, an oral drug, after a stem cell transplant can lower the chance of the cancer coming back in people with high-risk T-cell acute lymphoblastic leukemia or lymphoma. Participants are randomly assigned to receive chidamide for up to 24 months or standard follow-up. The study tracks relapse-free survival and overall survival to see if the maintenance therapy helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chidamide
- What this could lead to
- If effective, chidamide maintenance could become a standard post-transplant therapy to reduce relapse risk and improve survival in high-risk T-ALL/LBL patients.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. Chidamide may cause side effects like blood count changes or infections, and the benefit may not be confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- Experimental CAR-T therapy targets tough childhood blood cancers